Lipocine Inc. reported a third-quarter net loss of $0.7 million, or ($0.08) per diluted share, on revenue of $2.3 million, driven by $2.1 million in license and collaboration income and $190,000 in TLANDO royalties. Cash and equivalents rose to $21.5 million at quarter-end, with approximately $28.5 million available as of early November. The company initiated the Phase 3 BLOOM study for its postpartum depression candidate LPCN 1154 (BRLIZIO) following FDA feedback requiring a positive trial for NDA submission under the 505(b)(2) pathway. Lipocine is a biopharmaceutical company developing oral therapeutics using proprietary drug-delivery technology.
